Fair value · Addex Therapeutics Ltd. (ADXN) · updated 2026-09-20 · from 20-F FY2025
Addex Therapeutics trades at $3.40. We are not reading assumptions out of that price: financials are filed in CHF; our prices are in USD, so these methods need a conversion we do not yet publish.
Everything below is unaffected: the filed statements, the filing they came from, and ADXN’s growth history are all as reported.
The filing behind these numbers
Addex Therapeutics Ltd.- Revenue
- CHF 29972
- Diluted EPS
- CHF -0.06
- Free cash flow
- CHF -2.1M
- operating cash flow − capital expenditure
- Diluted shares
- 107.4M
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-05-15 · accession 0001104659-26-062447
Open this filing on sec.govNeed ADXN data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.